Page 347 - ACCCN's Critical Care Nursing

324 P R I N C I P L E S A N D P R A C T I C E O F C R I T I C A L C A R E

102. Wade CR, Reith KK, Sikora JH, Augustine SM. Postoperative nursing care of 128. Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW. A
the cardiac transplant recipient. Crit Care Nurs Q 2004; 27(1): 17–28. prospective randomized trial of arginine vasopressin in the treatment of
103. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung vasodilatory shock after left ventricular assist device placement. Circulation
Transplant 2004; 23(5 Suppl): S202–6. 1997; 96(9 Suppl): 286–90.
104. Morris PJ, Monaco AP. A meta-analysis from the Cochrane Library reviewing 129. Ardehali A, Hughes K, Sadeghi A, Esmailian F, Marelli D et al. Inhaled nitric
interleukin 2 receptor antagonists in renal transplantation. Transplantation oxide for pulmonary hypertension after heart transplantation. Transplanta-
2004; 77(2): 165. tion 2001; 72(4): 638–41.
105. Farmer DG, McDiarmid SV, Edelstein S, Renz JF, Hisatake G et al. Induction 130. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric
therapy with interleukin-2 receptor antagonist after intestinal transplantation oxide for the adult respiratory distress syndrome. N Eng J Med 1993; 328(6):
is associated with reduced acute cellular rejection and improved renal func- 399–405.
tion. Transplantat Proc 2004; 36(2): 331–2. 131. Armitage JM, Hardesty RL, Griffith BP. Prostaglandin E1: an effective treat-
106. Carey JA, Frist WH. Use of polyclonal antilymphocytic preparations for ment of right heart failure after orthotopic heart transplantation. J Heart Lung
prophylaxis in heart transplantation. J Heart Transplant 1990; 9(3 Pt 2): Transplant 1987; 6(6): 348–51.
297–300. 132. Wang SS, Ko WJ, Chen YS, Hsu RB, Chou NK, Chu SH. Mechanical bridge
107. Williams TJ, Snell GI. Lung transplantation. In: Albert RK, Spiro SG, Jett JR, with extracorporeal membrane oxygenation and ventricular assist device to
eds. Clinical respiratory medicine. Mosby; 2004. p. 831–45. heart transplantation Artif Organs 2001; 25(8): 599–602.
108. Mason JW, Stinson EB, Hunt SA, Schroeder JS, Rider AK. Infections after 133. Ellenbogen KA, Thames MD, DiMarco JP, Sheehan H, Lerman BB. Electro-
cardiac transplantation: relation to rejection therapy. Ann Intern Med 1976; physiological effects of adenosine in the transplanted human heart: evidence
85(1): 69–72. of supersensitivity. Circulation 1990; 81(3): 821–8.
109. Miller LW, Naftel DC, Bourge RC, Kirklin JK, Brozena SC et al. Infection after 134. Macdonald P, Hackworthy R, Keogh A, Sivathasan C, Chang V, Spratt P. Atrial
heart transplantation: a multiinstitutional study. Cardiac Transplant Research overdrive pacing for reversion of atrial flutter after heart transplantation.
Database Group. J Heart Lung Transplant 1994; 13(3): 381–92. J Heart Lung Transplant 1991; 10(5 Pt 1): 731–7.
110. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful inter- 135. Mackintosh AF, Carmichael DJ, Wren C, Cory-Pearce R, English TA. Sinus
mittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Eng J Med node function in first three weeks after cardiac transplantation. Br Heart
1987; 316(26): 1627–32. J 1982; 48(6): 584–8.
111. Kocher AA, Bonaros N, Dunkler D, Ehrlich M, Schlechta B et al. Long-term 136. Stark RP, McGinn AL, Wilson RF. Chest pain in cardiac-transplant recipients:
results of CMV hyperimmune globulin prophylaxis in 377 heart transplant evidence of sensory reinnervation after cardiac transplantation. N Eng J Med
recipients. J Heart Lung Transplant 2003; 22(3): 250–57. 1991; 324(25): 1791–4.
112. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M et al. The Inter- 137. Parry A, Roberts M, Parameshwar J, Wallwork J, Schofield P, Large S. The
national Society of Heart and Lung Transplantation Guidelines for the management of post-cardiac transplantation coronary artery disease. Eur J
care of heart transplant recipients. J Heart Lung Transplant 2010; 29(8): Cardiothorac Surg 1996; 10(7): 528–32.
914–56. 138. Shiba N, Chan MC, Kwok BW, Valantine HA, Robbins RC, Hunt SA. Analysis
113. Couchoud C. Cytomegalovirus prophylaxis with antiviral agents for solid of survivors more than 10 years after heart transplantation in the cyclospo-
organ transplantation. Cochrane Database Syst Rev 2000; 2: CD001320. rine era: Stanford experience. J Heart Lung Transplant 2004; 23(2): 155–64.
114. Walsh TR, Guttendorf J, Dummer S, Hardesty RL, Armitage JM et al. The 139. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk
value of protective isolation procedures in cardiac allograft recipients. Ann factors and management. J Heart Lung Transplant 2004; 23(5 Suppl):
Thorac Surg 1989; 47(4): 539–44. S187–93.
115. Wade CR, Reith KK, Sikora JH, Augustine SM. Postoperative nursing care of 140. Kobashigawa J. What is the optimal prophylaxis for treatment of cardiac
the cardiac transplant recipient. Crit Care Nurs Q 2004; 27(1): 17–28. allograft vasculopathy? Curr Control Trials Cardiovasc Med 2000; 1(3): 166.
116. Rourke TK, Droogan MT, Ohler L. Heart transplantation: state of the art. 141. Rose EA, Pepino P, Barr ML, Smith CR, Ratner AJ et al. Relation of HLA
AACN Clin Iss 1999; 10(2): 185–201. antibodies and graft atherosclerosis in human cardiac allograft recipients.
117. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M et al. A comparison J Heart Lung Transplant 1992; 11(3 Pt 2): S120–23.
of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative 142. Johnson DE, Alderman EL, Schroeder JS, Gao SZ, Hunt S et al. Transplant
blood products for the prevention of transfusion-associated CMV infection coronary artery disease: histopathologic correlations with angiographic mor-
after marrow transplant. Blood 1995; 86(9): 3598–603. phology. J Am Coll Cardiol 1991; 17(2): 449–57.
118. Luckraz HM, Goddard M, Charman SC, Wallwork J, Parameshwar J, Large 143. Keogh A, Richardson M, Ruygrok P, Spratt P, Galbraith A et al. Sirolimus in
SR. Early mortality after cardiac transplantation: should we do better? J Heart de novo heart transplant recipients reduces acute rejection and prevents
Lung Transplant 2005; 24(4): 401–5. coronary artery disease at 2 years: a randomized clinical trial. Circulation
119. Cooper DKC, Lidsky NM. Immediate postoperative care and potential 2004; 110(17): 2694–700.
complications. In: Cooper, DKC, Miller LW, Patterson GA, eds. The transplan- 144. Krikorian JG, Anderson JL, Bieber CP, Penn I, Stinson EB. Malignant
tation and replacement of thoracic organs, 2nd edn. London: Kluwer; 1996. neoplasms following cardiac transplantation. JAMA 1978; 240(7): 639–43.
p. 221–7 145. Ong CS, Keogh AM, Kossard S, Macdonald PS, Spratt PM. Skin cancer in
120. Taylor DO. Cardiac transplantation: drug regimens for the 21st century. Ann Australian heart transplant recipients. J Am Acad Dermatol 1999; 40(1):
Thorac Surg 2003; 75(6 Suppl): S72–8. 27–34.
121. McCrystal GD, Pepe S, Esmore DS, Rosenfeldt FL. The challenge of improv- 146. Veness MJ, Quinn DI, Ong CS, Keogh AM, Macdonald PS et al. Aggressive
ing donor heart preservation. Heart Lung Circ 2004; 13(1): 74–83. cutaneous malignancies following cardiothoracic transplantation: the
122. Rosenfeldt FL, McCrystal G, Pepe S, Esmore D. Myocyte or heart preservation: Australian experience. Cancer 1999; 85(8): 1758–64.
towards optimising donor heart quality [Conference Abstracts]. Cambridge, 147. Armitage JM, Kormos RL, Stuart RS, Fricker FJ, Griffith BP et al. Post-
England; 2002. transplant lymphoproliferative disease in thoracic organ transplant patients:
123. Esmore DS, Rosenfeldt FL, Mack JA, Waters KN, Bergin P. Long ischaemic time ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant
allografts (>6 hr) further expand the transplant donor pool. Washington: ISHLT 1991; 10(6): 877–86.
Conference Abstracts; 2002. 148. Cole WH. The increase in immunosuppression and its role in the develop-
124. Kieler-Jensen N, Lundin S, Ricksten SE. Vasodilator therapy after heart ment of malignant lesions. J Surg Oncol 1985; 30(3): 139–44.
transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, 149. Penn I, First MR. Development and incidence of cancer following cyclo-
prostaglandin E1, and sodium nitroprusside. J Heart Lung Transplant 1995; sporine therapy. Transplant Proc 1986; 18(2 Suppl 1): 210–15.
14(3): 436–43. 150. Penn I. Cancers following cyclosporine therapy. Transplantation 1987; 43(1):
125. Kristof AS, Magder S. Low systemic vascular resistance state in patients 32–5.
undergoing cardiopulmonary bypass. Crit Care Med 1999; 27(6): 151. Greenberg A, Thompson ME, Griffith BJ, Hardesty RL, Kormos RL et al.
1121–7. Cyclosporine nephrotoxicity in cardiac allograft patients – a seven-year
126. Myles PS, Leong CK, Currey J. Endogenous nitric oxide and low systemic follow-up. Transplantation 1990; 50(4): 589–93.
vascular resistance after cardiopulmonary bypass. J Cardiothorac Vasc Anaesth 152. Eisen HJ. Hypertension in heart transplant recipients: more than just cyclo-
1997; 11(5): 571–4. sporine. J Am Coll Cardiol 2003; 41(3): 433–4.
127. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S et al. Vasopressin 153. Ventura HO, Malik FS, Mehra MR, Stapleton DD, Smart FW. Mechanisms of
deficiency contributes to the vasodilation of septic shock. Circulation 1997; hypertension in cardiac transplantation and the role of cyclosporine. Curr
95(5): 1122–5. Opin Cardiol 1997; 12(4): 375–81.